MEDIA ALERT
FOR IMMEDIATE RELEASE
THE FUTURE LOOKS BRIGHT
CSL announces its latest scientific and medical breakthroughs in a research
and development briefing today
Thurs 10 December - CSL, Australia’s leading biopharmaceutical company, will today announce its latest
medical and scientific research in a briefing in Sydney.
CSL will present its latest innovations specifically relating to heart disease and serious gum disease.
CSL will reveal a novel vaccine designed to treat gum disease, which they have been developing for over 10
years in collaboration with the CRC for Oral Health Science and University of Melbourne.
Approximately thirty per cent of Australians have peridontitis or gum disease caused by a bacterial
infection that destroys the bone and tissue of the gum, causing teeth to fall out. The problem is that many
patients do not know they have it until it is in advanced stages and requires treatment such as surgery.
CSL will also discuss its latest research into plasma and cholesterol, leading to innovative treatments for
cardiovascular disease.
WHAT
The Future Looks Bright – CSL R&D briefing
DATE
Thursday 10 December 2009
WHERE:
The Beaumont Room, level one, Sheraton on the Park, 161 Elizabeth St Sydney
TIME:
12:45 pm for a 1:00 pm start, concluding at 2:00 pm (lunch provided)
FOR TELECONFERENCE DETAILS:
Please provide your contact number and email address to:
Erin Copping
02 8281 3252
erin@ogilvyprhealth.com
INTERVIEW, FILMING & PHOTO OPPORTUNITIES:
Professor Eric Reynolds, CEO of the Cooperative Research Centre for Oral Health Science; and Head
of Melbourne Dental School, University of Melbourne
Dr Andrew Cuthbertson, Chief Scientific Officer, CSL;
Dr Rachel David, Director of Public Affairs, CSL;
Dr Neil Hewson, national president of the Australian Dental Association
Jeannie, 42 year old woman with peridontitis
CONTACT
To arrange an interview, filming or photo opportunity, please contact:
Daniella Goldberg
02 8281 3219
0416 211 067
daniella@ogilvyprhealth.com
Erin Copping
02 8281 3252
0421 831 160
erin@ogilvyprhealth.com
NEWS 
